Skip to main
  1. Stocks
  2. Ideaya Biosciences Inc
  3. Forecast
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences is well positioned for a commercial inflection because darovasertib’s NDA was completed under RTOR in 3Q26, with broad mUM label potential supported by ESMO data across HLA-A2 positive and negative patients and a possible early 2027 launch. Its core value also comes from a differentiated synthetic-lethality platform, as IDE397 and IDE892 are advancing in MTAP-deleted tumors with projected efficacious exposure achieved and multiple RAS-combination studies underway, while IDE849 showed encouraging survival and response data that could support two phase III trials by YE26. Financially, the company reported $1.15B in cash and equivalents, expects runway into 2030, and is redirecting $100M-$125M of savings from the closed OptimUM-10 study toward higher-priority programs, reinforcing execution and optionality.

Bears say

IDEAYA Biosciences is viewed pessimistically because its valuation depends heavily on darovasertib succeeding in MUM or neo-adjuvant UM, and a failure there could leave the shares trading closer to cash at $10/share. The bearish case is reinforced by the risk of a disappointing PFS readout for daro in MUM, a challenged market opportunity in neo-adjuvant UM, and unclear paths to commercialization for pipeline programs. More broadly, clinical and regulatory failure of darovasertib, IDE397, or IDE849, along with possible safety signals, weak efficacy, or commercial competition from current and future therapies, could prevent the company from achieving sales estimates and undermine the investment thesis.

IDYA has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

IDYA Analyst Forecast & Price Prediction

Get the latest IDYA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IDYA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 11 analysts, IDYA has a Buy consensus rating as of Nov 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


IDYA Analyst Forecast & Price Prediction

Get the latest IDYA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IDYA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IDYA stock data and trends